DOCSLIB.ORG

Chapter 25. Parathyroid Hormone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 25. Parathyroid Hormone PARATHYROIDHORMONE 1 123 68. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, 77. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooper- Vanderschueren D 2002 Evidence from the aged orchidectomized berg C. Stefanick ML, Jackson RD, Beresford SA, Howard BV, male rat model that 17beta-estradiol is a more effective bone- Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of sparing and anabolic agent than 5alpha-dihydrotestosterone. J estrogen plus progestin in healthy postmenopausal women: Prin- Bone Miner Res 17:2080-2086. cipal results From the Women’s Health Initiative randomized con- 69. Venken K, Boonen S, Van Herck E, Vandenput L, Kumar N, trolled trial. JAMA 288:321-333. Sitruk-Ware R. Sundaram K. Bouillon R. Vanderschueren D 2005 78. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Bone and muscle protective potential of the prostate-sparing syn- Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, thetic androgen 7alpha-methyl-19-nortestosterone: Evidence from Curb D, Gass M. Hays J, Heiss G, Hendrix S, Howard BV, Hsia the aged orchidectomized male rat model. Bone 36:663-670. J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, 70. Slemenda CW, Longcope C, Zhou L, Hui SL, Pcacock M, John- Kuller L. LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, ston CC 1997 Sex steroids and bone mass in older men. Positive Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Pren- associations with serum estrogens and negative associations with tice RL. Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefan- androgens. J Clin Invest 100:1755-1759. ick ML. Van Horn L, Wactawski-Wende J, Wallace R, Wasser- 71. Greendale G, Edelstein S, Barrett-Connor E 1997 Endogenous theil-Smoller S 2004 Effects of conjugated equine estrogen in sex steroids and bone mineral density in older women and men. postmenopausal women with hysterectomy: The Women’s Health The Rancho Bernard0 Study. J Bone Miner Res 12:1833-1841. Initiative randomized controlled trial. JAMA 291:1701-1712. 72. Van Pottelbergh I, Goemaere S, Kaufman JM 2003 Bioavailable 79. Smith CL, O’Malley BW 2004 Coregulator function: A key to estradiol and an aromatase gene polymorphism are determinants understanding tissue specificity of selective receptor modulators. of bone mineral density changes in men over 70 years of age. J Clin Endocr Rev 25:45-71. Endocrinol Metab 88:3075-3081. 80. Anonymous 1998 Tamoxifen for early breast cancer: An overview 73. Riggs BL, Khosla S, Melton LJ IT1 1998 A unitary model for of the randomised trials. Early Breast Cancer Trialists’ Collabo- involutional osteoporosis: Estrogen deficiency causes both type I rative Group. Lancet 351:1451-1467. and type 11 osteoporosis in postmenopausal women and contrib- 81. Johnell 0, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, utes to bone loss in aging men. J Bone Miner Res 13:763-773. Zhou C, Pavo I 2004 Associations between baseline risk factors 74. Eastell R 2007 Aromatase inhibitors and bone. J Steroid Biochem and vertebral fracture risk in the Multiple Outcomes of Raloxifene Mol Biol 106:157-161. Evaluation (MORE) Study. J Bone Miner Res 19:764-772. 75. Snyder PJ, Peachey H. Hannoush P, Berlin JA, Loh L, Holmes JH, 82. Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2006 Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF. Haddad Anti-vertebral fracture efficacy of raloxifene: A meta-analysis. Os- JG Jr, Strom BL 1999 Effect of testosterone treatment on bone teoporos Int 17:313-316. mineral density in men over 65 years of age. J Clin Endocrinol 83. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW Metab 84:1966-1972. 1995 Analysis of estrogen receptor function in vitro reveals three 76. Kenny AM, Prestwood KM, Marcello KM, Raisz LG 2000 Deter- distinct classes of antiestrogens. Mol Endocrinol 9:659469. minants of bone density in healthy older men with low testoster- 84. Chen J, Kim J, Dalton JT 2005 Discovery and therapeutic promise one levels. J Gerontol A Biol Sci Med Sci 55A:M492-M497. of selective androgen receptor modulators. Mol Interv 5:173-188. Chapter 25. Parathyroid Hormone Robert A. Nissenson’ and Harald Juppner2 ‘Endocrine Research Unit, VA Medical Center, Departments of Medicine and Phjwiology, University of California, Sun Francisco, California; ‘Endocrine Unit and Pediatric Nephrology Unit, Departments o,f Medicine and Pediatrics, Harvard Medical School, Massachusetts General Hospitcil, Bostoii, Mrrssachusetts INTRODUCTION narrow limits over a wide range of dietary calcium intake. This chapter summarizes our current understanding of the biology The parathyroid glands first appear during evolution with the of PTH secretion and action. A nice historical perspective on movement of animals from an aquatic environment to a ter- this field has recently been published,(i) restrial environment deficient in calcium. Maintenance of ad- equate levels of plasma ionized calcium (1.0-1.3 mM) is re- quired for normal neuromuscular function, bone THE PTH POLYPEPTIDE FAMILY mineralization, and many other physiological processes. Chief Mammalian PTH is a single-chain 84 amino acid polypep- cells in the parathyroid gland secrete PTH in response to very tide hormone that is expressed almost exclusively in the para- small decrements in blood ionized calcium to maintain the thyroid gland, with lesser expression in the rodent hypothala- normocalcemic state. As discussed later, PTH accomplishes mus and thymus. The appearance of PTH precedes that of the this task by promoting bone resorption and releasing calcium parathyroid gland in evolution, because two forms of PTH from the skeletal reservoir; by inducing renal conservation of have been detected in teleosts that lack discrete parathyroid calcium and excretion of phosphate; and by indirectly enhanc- glands.(*.3) The physiological roles of PTH in fish have not yet ing intestinal calcium absorption by increasing the renal pro- been definitively established, although it has suggested based duction of the active vitamin D metabolite 1,25(OH), vitamin on sites of expression that PTH may play a role in the devel- D. Serum ionized calcium and 1,25(OH), vitamin D produce opment of the teleost neural system, cartilage, and bone.(4) feedback inhibition of the secretion of PTH, whereas serum Teleost PTHs display significant amino acid homology to phosphate increases PTH secretion. The interplay between se- mammalian PTHs in the 1-34 sequence of the mature peptides rum calcium, PTH, 1,25(OH), vitamin D, and phosphate per- (i.e., the region required for binding to and activating the G- mit serum ionized calcium levels to be maintained within very protein-coupled PTHl receptor; Fig. 1).Teleosts display wide- spread expression of a PTHl receptor that presumably medi- The authors state that they have no conflicts of interest. ates the physiological actions of PTH. 0 2008 American Society for Bone and Mineral Research 124 I CHAPTER25 PTH, PTHrP, and TIP39 is reflected in the organization of the genes encoding these polypeptides (Fig. 2). PTH SYNTHESIS AND SECRETION There is a single mammalian PTH gene that in humans is present on the short arm of chromosome 11. The primary translation product is the precursor molecule prepro-PTH that includes a 25 amino acid pre sequence, a 6 amino acid pro IChickPTH PTH - sequence, and an 84 amino acid mature PTH sequence.(13)The zPTHl pre sequence functions as a signal sequence that directs the nascent polypeptide to the machinery that transports it across fPTHl the membrane of the endoplasmic reticulum (ER), where the - pre sequence is cleaved. The function of the pro sequence is not as clearly defined, but it seems to be required for efficient ER transport of the polypeptide and may play a role in sub- sequent events such as protein folding.(I4)The pro sequence seems to be cleaved by the protease furin, producing the ma- rPTHrP1 ture 1-84 PTH polypeptide. Once produced and packaged into secretory vesicles with the parathyroid chief cell, PTH( 1-84) is mPTHrP PTHrP subject to alternative fates. The mature hormone can be se- creted through a classical exocytotic mechanism or it may be hPTHrPJ cleaved by calcium-sensitive proteases present within secretory vesicles, resulting in the production and secretion of fragments of PTH(1-84) that lack the amino-terminal domain and are thus inactive with respect to responses mediated by the PTHl receptor."') Cleavage of circulating PTH( 1-84) to carboxyl- fragments can also occur in peripheral tissues such as liver and GIP "l kidney.' '') Historically, cleavage of PTH( 1-84) has been viewed as a mechanism for biological inactivation of the hor- FIG. 1. Phylogenetic analysis of PTH and related polypeptides."' mone, but there is suggestive evidence that carboxyl-terminal Copyright 2004, The Endocrine Society. fragments of PTH may display unique biological properties.'") REGULATION OF PTH SECRETION BY PTH-related peptide (PTHrP) displays sequence homology EXTRACELLULAR CALCIUM with PTH that is limited to the amino-terminal 1-34 region of both peptides.'" PTHrP was originally identified as the hu- The major physiological function of the parathyroid glands moral mediator of hypercalcemia of malignan~y'~ and is is to act as a "calciostat," sensing the prevailing blood ionized now known to play a number of important physiological roles calcium level and adjusting the secretion of PTH accordingly (eg, control of endochondral bone development, smooth (Fig. 3). The relationship between ionized calcium and PTH muscle tone, and morphogenesis of the mammary gland).'x' secretion is a steep sigmoidal one, allowing significant changes The PTHrP gene has structural similarity to that of PTH, and in PTH secretion in response to very small changes in plasma the genes are presumed to be derived from a common ances- ionized calcium.
Load more

Recommended publications
  • WO 2013/096741 A2 27 June 2013 (27.06.2013) P CT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/096741 A2 27 June 2013 (27.06.2013) P CT (51) International Patent Classification: (74) Agents: GEORGE, Nikolaos C. et al; Jones Day, 222 A61K 35/12 (2006.01) East 41st Street, New York, NY 10017-6702 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 12/07 1192 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) Date: International Filing BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 2 1 December 2012 (21 .12.2012) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 61/579,942 23 December 201 1 (23. 12.201 1) US RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/592,350 30 January 2012 (30.01.2012) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 61/696,527 4 September 2012 (04.09.2012) us ZM, ZW. (71) Applicant: ANTHROGENESIS CORPORATION (84) Designated States (unless otherwise indicated, for every [US/US]; 33 Technology Drive, Warren, NJ 07059 (US).
    [Show full text]
  • The Fine Structure of the Parathyroid Gland*
    The Fine Structure of the Parathyroid Gland* BY JERRY STEVEN TRIER, M.D. (From the Department of Anatomy, University of Washington School of Medicine, Seattle) PLATES 3 TO 10 (Received for publication, July 29, 1957) ABSTRACT The fine structure of the parathyroid of the macaque is described, and is cor- related with classical parathyroid cytology as seen in the light microscope. The two parenchymal cell types, the chief cells and the oxyphil cells, have been recognized in electron mierographs. The chief cells contain within their cyto- plasm mitochondria, endoplasmic reticulum, and Golgi bodies similar to those found in other endocrine tissues as well as frequent PAS-positive granules. The juxtanuclear body of the light microscopists is identified with stacks of parallel lamellar elements of the endoplasmic rcticulum of the ergastoplasmic or granular type. Oxyphll cells are characterized by juxtanuclear bodies and by numerous mito- chondria found throughout their cytoplasm. Puzzling lamellar whorls are described in the cytoplasm of some oxyphil cells. The endothelium of parathyroid capillaries is extremely thin in some areas and contains numerous fenestrations as well as an extensive system of vesicles. The possible significance of these structures is discussed. The connective tissue elements found in the perivascular spaces of macaque parathyroid are described. INTRODUCTION Other contributions to the present concepts con cerning the human parathyroid can be found in the It is the purpose of the present paper to report some observations on the fine structure of the reports of Bergstrand (7), Morgan (34), Pappen- parathyroid gland employing the electron micro- heimer and Wilens (45), Castleman and Mallory (10), and Gilmour (20).
    [Show full text]
  • WO 2015/168656 A2 5 November 2015 (05.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/168656 A2 5 November 2015 (05.11.2015) P O P C T (51) International Patent Classification: (72) Inventors: HSIAO, Sonny; 1985 Pleasant Valley Avenue, A61K 48/00 (2006.01) Apartment 7, Oakland, CA 9461 1 (US). LIU, Cheng; 24 N Hill Court, Oakland, CA 94618 (US). LIU, Hong; 5573 (21) International Application Number: Woodview Drive, El Sobrante, CA 94803 (US). PCT/US20 15/02895 1 (74) Agents: GIERING, Jeffery, C. et al; Wilson Sonsini (22) International Filing Date: Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 1 May 2015 (01 .05.2015) 94304-1050 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (30) Priority Data: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 61/988,070 2 May 2014 (02.05.2014) US DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) Applicant: ADHEREN INCORPORATED [US/US]; HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 1026 Rispin Drive, Berkeley, CA 94705 (US). KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (72) Inventors; and PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (71) Applicants : TWITE, Amy, A.
    [Show full text]
  • Nomenclatore Per L'anatomia Patologica Italiana Arrigo Bondi
    NAP Nomenclatore per l’Anatomia Patologica Italiana Versione 1.9 Arrigo Bondi Bologna, 2016 NAP v. 1.9, pag 2 Arrigo Bondi * NAP - Nomenclatore per l’Anatomia Patologica Italiana Versione 1.9 * Componente Direttivo Nazionale SIAPEC-IAP Società Italiana di Anatomia Patologica e Citodiagnostica International Academy of Pathology, Italian Division NAP – Depositato presso S.I.A.E. Registrazione n. 2012001925 Distribuito da Palermo, 1 Marzo 2016 NAP v. 1.9, pag 3 Sommario Le novità della versione 1.9 ............................................................................................................... 4 Cosa è cambiato rispetto alla versione 1.8 ........................................................................................... 4 I Nomenclatori della Medicina. ........................................................................................................ 5 ICD, SNOMED ed altri sistemi per la codifica delle diagnosi. ........................................................... 5 Codifica medica ........................................................................................................................... 5 Storia della codifica in medicina .................................................................................................. 5 Lo SNOMED ............................................................................................................................... 6 Un Nomenclatore per l’Anatomia Patologica Italiana ................................................................. 6 Il NAP .................................................................................................................................................
    [Show full text]
  • Wednesday Slide Conference 2008-2009
    PROCEEDINGS DEPARTMENT OF VETERINARY PATHOLOGY WEDNESDAY SLIDE CONFERENCE 2008-2009 ARMED FORCES INSTITUTE OF PATHOLOGY WASHINGTON, D.C. 20306-6000 2009 ML2009 Armed Forces Institute of Pathology Department of Veterinary Pathology WEDNESDAY SLIDE CONFERENCE 2008-2009 100 Cases 100 Histopathology Slides 249 Images PROCEEDINGS PREPARED BY: Todd Bell, DVM Chief Editor: Todd O. Johnson, DVM, Diplomate ACVP Copy Editor: Sean Hahn Layout and Copy Editor: Fran Card WSC Online Management and Design Scott Shaffer ARMED FORCES INSTITUTE OF PATHOLOGY Washington, D.C. 20306-6000 2009 ML2009 i PREFACE The Armed Forces Institute of Pathology, Department of Veterinary Pathology has conducted a weekly slide conference during the resident training year since 12 November 1953. This ever- changing educational endeavor has evolved into the annual Wednesday Slide Conference program in which cases are presented on 25 Wednesdays throughout the academic year and distributed to 135 contributing military and civilian institutions from around the world. Many of these institutions provide structured veterinary pathology resident training programs. During the course of the training year, histopathology slides, digital images, and histories from selected cases are distributed to the participating institutions and to the Department of Veterinary Pathology at the AFIP. Following the conferences, the case diagnoses, comments, and reference listings are posted online to all participants. This study set has been assembled in an effort to make Wednesday Slide Conference materials available to a wider circle of interested pathologists and scientists, and to further the education of veterinary pathologists and residents-in-training. The number of histopathology slides that can be reproduced from smaller lesions requires us to limit the number of participating institutions.
    [Show full text]
  • Differentiation of Human Parathyroid Cells in Culture
    417 Differentiation of human parathyroid cells in culture W Liu, P Ridefelt1, G Åkerström and P Hellman Department of Surgery, University Hospital, Uppsala, Sweden 1Clinical Chemistry, University Hospital, Uppsala, Sweden (Requests for offprints should be addressed to P Hellman, Department of Surgery, University Hospital, SE-751 85 Uppsala, Sweden; Email: [email protected]) Abstract Continuous culture of parathyroid cells has proven diffi- histochemistry for proliferating cell nuclear antigen and cult, regardless from which species the cells are derived. In cell counting. Signs of differentiation were present as the the present study, we have used a defined serum-free low set-points, defined as the external calcium concentration at 2+ calcium containing medium to culture human parathyroid which half-maximal stimulation of [Ca ]i (set-pointc), or cells obtained from patients with parathyroid adenomas half-maximal inhibition of PTH release (set-pointp) occur, due to primary hyperparathyroidism. No fibroblast over- were higher in not proliferating compared with prolifer- growth occurred, and the human parathyroid chief cells ating cells in P0. Inhibition of cell proliferation was proliferated until confluent. After the first passage the cells accompanied by signs of left-shifted set-points, indicating ceased to proliferate, but still retained their functional a link between proliferation and differentiation. capacity up to 60 days, demonstrated by Ca2+-sensitive The results demonstrate that human parathyroid chief changes in the release of parathyroid hormone (PTH) and cells cultured in a defined serum-free medium can be kept 2+ ff as adequate cytoplasmic calcium ([Ca ]i) responses to viable for a considerable time, and that signs of di er- changes in ambient calcium as measured by micro- entiation occur after proliferation has ceased.
    [Show full text]
  • Introduction to the Endocrine System: Mechanisms of Disease
    Introduction to the Endocrine System: Mechanisms of Disease Mark J. Hoenerhoff, DVM, PhD, DACVP Associate Professor, In Vivo Animal Core Unit for Laboratory Animal Medicine University of Michigan Medical School 1.1 Lairmore and Rosol, Vet Pathol. 2008 May;45(3):285-286. 1.2 HORMONES CONTROL EVERYTHING!! 1.3 quora.com “CAPEN’S TEN LAWS” OF ENDOCRINE DISEASE 1. Primary Hyperfunction 2. Secondary Hyperfunction 3. Primary Hypofunction 4. Secondary Hypofunction 5. Endocrine Hyperactivity 2o to Other Organ Disease 6. Hypersecretion of Hormones by Non-endocrine Tumors 7. Endocrine Dysfunction due to Failure of Target Cell Response 8. Failure of Fetal Endocrine Function 9. Endocrine Dysfunction 2o to Abnormal Hormone Degradation 10. Syndromes of Iatrogenic Hormone Excess 1.4 Capen CC. Endocrine Glands. In: Maxie G, ed. Jubb, Kennedy & Palmer’s Pathology of Domestic Animals. 5th ed. Elsevier; 2007:325-326. Papadopoulos and Cleare, Nat Rev Endocrinol. 2011 Sept 27;8(1):22-32 1.5 Bassett and Williams, Bone. 2008 Sep;43(3):418-426. 1. PRIMARY HYPERFUNCTION OF ENDOCRINE ORGANS • Often result of functional neoplastic disease of endocrine gland • Autonomous secretion of hormones – DIRECT effect on target organ • Outpaces body’s ability to utilize and degrade hormone • Functional disturbance of hormone excess • Parathyroid chief cell tumors Hyperparathyroidism • Thyroid follicular tumors Hyperthyroidism 1.6 1. PRIMARY HYPERFUNCTION • Parathyroid tumors Hyperparathyroidism Parathyroid PTH Solar Arias et al, Open Vet J. 2016;6(3):165-171. 1.7 Bassett and Williams, Bone. 2008 Sep;43(3):418-426. 1. PRIMARY HYPERFUNCTION • Parathyroid tumors Hyperparathyroidism Parathyroid PTH https://ntp.niehs.nih.gov/nnl/index.htmSolar Arias et al, Open Vet J, 2016 1.7 Bassett and Williams, Bone.
    [Show full text]
  • Thyroid Gland
    10/13/2020 STP Virtual Modular Course 1 Thyroid/Parathyroid: Normal, Background, Induced; Rodent/Nonrodent Terminology; Rodent-Specific Effects I and II Thomas J. Rosol, DVM, PhD, MBA, DACVP, Ohio University Heritage College of Medicine See INHAND: Endocrine (rodents, dog) 2 ©Rosol 2020 1 10/13/2020 Thyroid Gland • Evolution: Conservation of T4 and T3 (mammals, birds, and teleosts) • Structure: Similar • Physiology and metamorphosis: Similarities and dissimilarities • Cancer: Dissimilarities 3 4 ©Rosol 2020 2 10/13/2020 Thyroid Stimulating Hormone (TSH) • Glycoprotein: Alpha & Beta (novel) subunits • Short (~15 minute) half-life • Circulates free (unbound) in blood • Highly species-specific – Human, primate, rat, & dog assays – Little cross reactivity – Male rats greater than females 5 Negative Feedback of the Pituitary by Free T4 • Feedback is dependent on the free hormone – Hypothalamus – Pituitary •Pituitary – 5’ Deiodinase (D2) (intracellular on ER) – Converts T4 to T3 – Serum free T4 correlates with TSH secretion 6 ©Rosol 2020 3 10/13/2020 Relationship of TSH to Free T4 TSH (ng/ml) Free T4 (pM) 7 T4 dose and serum TSH in hypothyroid dog Ferguson DC, 2009, Vet Pharm & Ther 8 ©Rosol 2020 4 10/13/2020 Mouse: TSH Cell Hypertrophy & Hyperplasia (Inhibition of thyroxine synthesis) 9 NIS IHC: 2-month-old Mouse 10 ©Rosol 2020 5 10/13/2020 NIS IHC: 9-month-old Mouse 11 12 ©Rosol 2020 6 10/13/2020 Thyroid Hormone Deiodination • Circulating T3 is not useful to measure thyroid function –Source: liver & kidney plasma membrane deiodinase 1 (D1) • T3 is largely regulated at the cellular level in a tissue- dependent manner (by 5’ deiodinase, D2) 13 Free Serum T4 Between Species TT4 FT4 FT4 Half-life Species (g/dL) (%) (ng/dl) (hours) Rat 4.1 0.05 2.0 13 Dog 2.8 0.10 2.8 15 Cat 1.7 0.10 1.7 11 Human 6.8 0.03 2.0 120 TT4: Total T4, FT4: Free T4 14 ©Rosol 2020 7 10/13/2020 15 Thyroxine Pharmacokinetics Dog and Human (0.22 L/hr) (0.05 L/hr) Kaptein, Am.
    [Show full text]
  • W O 2017/180669 a L 1 9 October 2017 (19.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/180669 A l 1 9 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12N 15/90 (2006.01) C12N 15/09 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 15/87 (2006.01) C07H 21/04 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/US20 17/027073 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 11 April 2017 ( 11.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/320,863 11 April 2016 ( 11.04.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: APPLIED STEMCELL, INC.
    [Show full text]
  • Parsabiv H-3995
    15 September 2016 EMA/664198/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Parsabiv International non-proprietary name: etelcalcetide Procedure No. EMEA/H/C/003995/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 8 2.1. Introduction ........................................................................................................ 8 2.1.1. Problem statement ............................................................................................ 8 2.1.2. About the product ............................................................................................. 9 2.2. Quality aspects ...................................................................................................
    [Show full text]
  • The Role of Protein Kinase C in the Extracellular Ca2+-Regulated Secretion of Parathyroid Hormone
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1384 The Role of Protein Kinase C in the Extracellular Ca2+-regulated Secretion of Parathyroid Hormone BY AMOS M. SAKWE ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2004 !" !# $ % & ' % % (& & ) % * +, -& . / '&, 0 1. 2 *, !#, -& 3 % ( 4 & / !56' 0 % ( & 7 , 2 , 8#, #6 p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n memory of
    [Show full text]
  • Water-Clear Cell Adenoma of the Mediastinal Parathyroid Gland
    Case Report doi: 10.5146/tjpath.2017.01407 Water-Clear Cell Adenoma of the Mediastinal Parathyroid Gland Deniz ARIK1, Emine DÜNDAR1, Evrim YILMAZ1, Cumhur SİVRİKOZ2 Department of 1Pathology and 2Thorax Surgery, Eskisehir Osmangazi University, Medicine Faculty, ESKİŞEHİR, TURKEY ABSTRACT Water-clear cell adenoma of the parathyroid gland is a rare neoplasm that consists of cells with abundant clear-pink cytoplasm. There have only been 19 cases reported in the English literature. Here we report a case of water-clear cell adenoma of the mediastinal parathyroid gland. A 70-year-old male patient presented to the hospital with back pain and a mediastinal mass 6 cm in size was detected. After excision and microscopic evaluation, uniform, large clear cells with fine cytoplasmic vacuolization, without nuclear atypia, and arranged in solid and acinar patterns were revealed. The cells formed nests that were separated by fine fibrovascular septae and stained positively with anti-parathyroid hormone. To the best of our knowledge, this has not been previously reported in this location. In the differential diagnosis of clear cell lesions of the mediastinum, water-clear cell parathyroid adenoma should be considered. Key Words: Water-clear cell, Adenoma, Ectopic tissue, Mediastinum, Parathyroid gland INTRODUCTION did not have high glycolytic activity. The serum calcium and parathyroid hormone levels were not evaluated. Surgical Water-clear cell parathyroid adenoma (WCCA) is very excision was planned by the initial diagnosis of a bronchial rare. Only nineteen cases have been reported in the English cyst, pathological lymph node or low-grade malignancy. literature (1-17). Water-clear cells (WCCs) are large In open surgery, by intraoperative consultation (frozen polygonal cells with a small nucleus and large optically section) of the biopsy, a lesion with clear cells was seen, but clear cytoplasm.
    [Show full text]